drugset
drugset / Trial / NCT06152042

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042 ↗

Phase 2 Terminated 37 enrolled Biomea Fusion Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Timeline

Start
2023-12-28
Primary completion
2025-05-20
Completion
2025-07-18

Outcome

Outcome not reported

Stopped (Business): “Sponsor made a business decision to terminate the study based on prioritization of portfolio.”

Drugs

EvaluationDrugModalityDoseRoute
Subject icovamenib Small molecule 100 mg Oral
Subject icovamenib Small molecule 200 mg Oral

Indications

type 1 diabetes mellitus